BioMarin Pharmaceutical | BMRN - Ebitda


BioMarin Pharmaceutical reported $146.05M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amgen USD 3.86B 1.28B Mar/2026
Bayer EUR 2.14B 2.31B Jun/2026
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
Incyte USD 778.57M 410.6M Jun/2026
Insmed USD 12.73M 161.04M Jun/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
Moderna USD -1.26B 468M Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 2.72B 2.94B Mar/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
United Therapeutics USD 355M 11.1M Jun/2026
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026